Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ALKS
- Price
- 32.90
- Stock movement down
- -0.09 (-0.28%)
- Company name
- Alkermes Plc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 5.27B
- Ent value
- 5.25B
- Price/Sales
- 3.46
- Price/Book
- 3.04
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 15.55
- Forward P/E
- 15.57
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -10.97%
- 3 year return (CAGR)
- 4.87%
- 5 year return (CAGR)
- 9.55%
- 10 year return (CAGR)
- 0.94%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ALKS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 15.55 |
| Price to OCF | 9.74 |
| Price to FCF | 10.73 |
| Price to EBITDA | 12.09 |
| EV to EBITDA | 12.04 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.46 |
| Price to Book | 3.04 |
| EV to Sales | 3.45 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 165.12M |
| EPS (TTM) | 2.01 |
| FCF per share (TTM) | 2.91 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.52B |
| Gross profit (TTM) | 1.31B |
| Operating income (TTM) | 358.54M |
| Net income (TTM) | 338.83M |
| EPS (TTM) | 2.01 |
| EPS (1y forward) | 2.05 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 86.04% |
| Operating margin (TTM) | 23.57% |
| Profit margin (TTM) | 22.27% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 616.45M |
| Net receivables | 355.11M |
| Total current assets | 1.74B |
| Goodwill | 0.00 |
| Intangible assets | 83.86M |
| Property, plant and equipment | 589.70M |
| Total assets | 2.33B |
| Accounts payable | 68.00M |
| Short/Current long term debt | 71.60M |
| Total current liabilities | 474.36M |
| Total liabilities | 596.08M |
| Shareholder's equity | 1.73B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 541.08M |
| Capital expenditures (TTM) | 50.21M |
| Free cash flow (TTM) | 490.87M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 19.55% |
| Return on Assets | 14.54% |
| Return on Invested Capital | 19.47% |
| Cash Return on Invested Capital | 28.21% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 31.80 |
| Daily high | 31.99 |
| Daily low | 31.40 |
| Daily Volume | 1.82M |
| All-time high | 98.06 |
| 1y analyst estimate | 43.81 |
| Beta | 0.46 |
| EPS (TTM) | 2.01 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ALKS | S&P500 | |
| Current price drop from All-time high | -66.45% | -1.82% |
| Highest price drop | -96.15% | -56.47% |
| Date of highest drop | 11 Jul 2002 | 9 Mar 2009 |
| Avg drop from high | -67.28% | -10.84% |
| Avg time to new high | 132 days | 12 days |
| Max time to new high | 6531 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.27B
Marketcap category
Mid-cap
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Employees
1800
Website
Investor relations
-
SEC filings
CEO
Richard F. Pops
Country
USA
City
Dublin D04
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page